Want to see AU:RCE full AI Analyst Report?

Recce Pharmaceuticals Ltd. (RCE) Price & Analysis

22 Followers

RCE Stock Chart & Stats

AU$0.36

AU$0.02(4.17%)

At close: Jul 27 4:00 PM EDT

AU$0.36

AU$0.02(4.17%)

Day’s Range― - ―

52-Week RangeAU$0.35 - AU$0.73

Previous CloseN/A

Volume134.82K

Average Volume (3M)154.69K

Market Cap

AU$109.31M

Enterprise ValueAU$198.04

Total Cash (Recent Filing)AU$602.99K

Total Debt (Recent Filing)AU$11.26M

Price to Earnings (P/E)―

Beta1.09

Next Earnings

Aug 28, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.12

Shares Outstanding299,468,800

10 Day Avg. Volume112,630

30 Day Avg. Volume154,688

Financial Highlights & Ratios

PEG Ratio0.34

Price to Book (P/B)-22.52

Price to Sales (P/S)9.15

P/FCF Ratio-3.36

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.1

Revenue Forecast (FY)AU$4.80M

Bulls Say, Bears Say

Bulls Say

Free Cash Flow ImprovementA 51.97% rise in free cash flow signals improving cash generation relative to prior periods. For a clinical-stage biotech this strengthens the funding runway for R&D and trials, reducing near-term financing pressure and supporting program continuity over months.

Return On EquityA positive ROE of 7.02% despite balance sheet stress suggests management can extract returns from available equity and resources. This operational efficiency points to competent capital deployment, valuable for advancing clinical programs and negotiating partnerships.

Diversified Anti-infective PipelineA portfolio spanning intravenous, oral and topical broad-spectrum candidates reduces single-program dependency and diversifies clinical and commercial risk. Targeting resistant pathogens aligns with structural demand for new antibiotics and expands potential regulatory and market pathways.

Bears Say

Revenue Decline & Negative MarginsA 21.73% revenue decline coupled with extreme negative margins (net -285.37%, EBIT -271.76%) reflects entrenched unprofitability and weakening commercial traction. Structural losses imply sustained funding needs and risk to executing clinical programs without dilution or external support.

Negative Equity And LeverageDebt-to-equity of -3.53 and negative equity indicate a strained capital structure that limits borrowing capacity and increases refinancing and covenant risks. Such balance sheet weakness constrains strategic flexibility and heightens funding vulnerability for costly development stages.

Insufficient Operating Cash GenerationOperating cash flow is not covering losses, with a negative operating cash flow to net income ratio. Persistent lack of cash from core operations forces dependency on external financing, raising dilution risk and potentially delaying clinical milestones and regulatory progress.

Recce Pharmaceuticals Ltd. News

Recce Raises A$6.4m via Placement and Share Purchase Plan, Adds Layered Option Incentives

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) has issued an update. Recce Pharmaceuticals has completed its Share Purchase Plan,...

1d ago

Recce Pharmaceuticals Seeks ASX Quotation for Over 6 Million New Shares

The latest update is out from Recce Pharmaceuticals Ltd. ( ($AU:RCE) ). Recce Pharmaceuticals Ltd has applied for...

1d ago

Recce Pharmaceuticals Calls September Virtual General Meeting for Shareholders

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) has provided an announcement. Recce Pharmaceuticals has called a virtual General Meeting...

1d ago

Recce Positioned as U.S. Unveils US$66.9 Billion Antimicrobial Biodefense Plan

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) has shared an announcement. The U.S. Administration for Strategic Preparedness and Response...

2d ago

Recce Wins Key Vietnamese Patent for Novel Anti-Infectives

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) has provided an update. Recce Pharmaceuticals has secured a Vietnamese patent for...

18d ago

Recce Pharmaceuticals Opens $4m Share Purchase Plan to Fund Anti-Infective Pipeline

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) just unveiled an announcement. Recce Pharmaceuticals has opened its previously announced share...

26d ago

Recce Pharmaceuticals Completes Share Placement and Issues Cleansing Notice

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) just unveiled an update. Recce Pharmaceuticals has completed the remaining tranche of...

29d ago

Recce Pharmaceuticals Seeks Quotation for 150,000 New ASX Shares

An announcement from Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) is now available. Recce Pharmaceuticals Ltd has applied for...

29d ago

Recce Pharmaceuticals Seeks ASX Quotation for New Incentive Shares

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) has issued an update. Recce Pharmaceuticals has applied for quotation of 35,399...

1M ago

Recce Pharmaceuticals Seeks ASX Quotation for 250,000 New Shares

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) has issued an announcement. Recce Pharmaceuticals Ltd. has applied for quotation on...

1M ago

RCE FAQ

What was Recce Pharmaceuticals Ltd.’s price range in the past 12 months?

Recce Pharmaceuticals Ltd. lowest share price was AU$0.35 and its highest was AU$0.73 in the past 12 months.

What is Recce Pharmaceuticals Ltd.’s market cap?

Recce Pharmaceuticals Ltd.’s market cap is AU$109.31M.

When is Recce Pharmaceuticals Ltd.’s upcoming earnings report date?

Recce Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 28, 2026 which is in 27 days.

How were Recce Pharmaceuticals Ltd.’s earnings last quarter?

Recce Pharmaceuticals Ltd. released its earnings results on Feb 27, 2026. The company reported -AU$0.057 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Recce Pharmaceuticals Ltd. overvalued?

According to Wall Street analysts Recce Pharmaceuticals Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Recce Pharmaceuticals Ltd. pay dividends?

Recce Pharmaceuticals Ltd. does not currently pay dividends.

What is Recce Pharmaceuticals Ltd.’s EPS estimate?

Recce Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Recce Pharmaceuticals Ltd. have?

Recce Pharmaceuticals Ltd. has 299,468,800 shares outstanding.

What happened to Recce Pharmaceuticals Ltd.’s price movement after its last earnings report?

Recce Pharmaceuticals Ltd. reported an EPS of -AU$0.057 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.917%.

Which hedge fund is a major shareholder of Recce Pharmaceuticals Ltd.?

Currently, no hedge funds are holding shares in AU:RCE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Recce Pharmaceuticals Ltd. Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-51.48%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Recce Pharmaceuticals Ltd.

Recce Pharmaceuticals Ltd operates as a biotechnology enterprise, concentrating on the research, advancement, and market introduction of synthetic anti-infective treatments across Australia, the United States, and the United Kingdom. The company's foremost developmental drug, RECCE 327, is intended to address blood infections and sepsis caused by E. coli and S. aureus bacteria, including their antibiotic-resistant variants. Additionally, Recce is progressing RECCE 529, a synthetic anti-infective targeting viral illnesses, and RECCE 435, another synthetic polymer anti-infective. Founded in 2007, the firm, which was initially named Recce Limited, officially became Recce Pharmaceuticals Ltd in November 2017. Its corporate headquarters are situated in Sydney, Australia.